In vitro activity of the lipopeptide derivative (Pal-lys-lys-NH 2), alone and in combination with antifungal agents, against clinical isolates of dermatophytes

British Journal of Dermatology

Volumn 161, Issue 2, 2009, Pages 249-252

  Simonetti, O ^a   Arzeni, D ^b   Ganzetti, G ^a   Silvestri, C ^b   Cirioni, O ^b   Gabrielli, E ^b   Castelletti, S ^b   Kamysz, W ^c   Kamysz, E ^d   Scalise, G ^b   Offidani, A ^a   Barchiesi, F ^b  

^a OSPEDALI RIUNITI   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d UNIVERSITY OF GDA SK   (Poland)

Author keywords

Antifungal; Dermatophytes; In vitro; Pal lys lys NH 2; Synergy

Indexed keywords

ANTIFUNGAL AGENT; LIPOPROTEIN; PAL LYS LYS NH2; PAL-LYS-LYS-NH2;

ARTHRODERMATACEAE; ARTICLE; DERMATOMYCOSIS; DRUG EFFECT; DRUG SCREENING; HUMAN; MICROBIOLOGICAL EXAMINATION;

ANTIFUNGAL AGENTS; ARTHRODERMATACEAE; DERMATOMYCOSES; DRUG EVALUATION, PRECLINICAL; HUMANS; LIPOPROTEINS; MICROBIAL SENSITIVITY TESTS;

EID: 73349096014     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2009.09166.x     Document Type: Article

References (33)

1. Kobayashi GS, Spitzer ED. Testing of organisms for susceptibility to triazoles: is it justified? Eur J Clin Microbiol Infect Dis 1989; 8:387-9.
2. Porro AM, Yoshioka MC, Kaminski SK et al. Disseminated dermatophytosis caused by Microsporum gypseum in two patients with the acquired immunodeficiency syndrome. Mycopathologia 1997; 137:9-12.
3. [No authors listed]. National casuistic of superficial and deep mycoses during 1999-2000. Presented at: The Annual Reunion of Mycology Groups. Maracaibo, Venezuela. 2000.
4. Gupta AK, Konnikov N, MacDonald P et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol 1998; 139:665-71.
5. Fernandez-Torres B, Cabanes FJ, Carrillo-Munoz AJ et al. Collaborative evaluation of optimal antifungal susceptibility testing conditions for dermatophytes. J Clin Microbiol 2002; 40:3999-4003.
6. Fernandez-Torres B, Carrillo AJ, Martin E et al. In vitro activities of 10 antifungal drugs against 508 dermatophyte strains. Antimicrob Agents Chemother 2001; 45:2524-8.
7. Debruyne D, Coquerel A. Pharmacokinetics of antifungal agents in onychomycoses. Clin Pharmacokinet 2001; 40:441-72.
8. Niewerth M, Korting HC. The use of systemic antimycotics in dermatotherapy. Eur J Dermatol 2000; 10:155-60.
9. Fernandez-Torres B, Vazquez-Veiga H, Llovo X et al. In vitro susceptibility to itraconazole, clotrimazole, ketoconazole and terbinafine of 100 isolates of Trichophyton rubrum. Chemotherapy 2000; 46:390-4.
10. Meinhof W. Kinetics and spectrum of activity of oral antifungals: the therapeutic implications. J Am Acad Dermatol 1993; 29:S37-41.
11. Barchiesi F, Arzeni D, Camiletti V et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001; 39:4208-9.
12. Sarifakioglu E, Seckin D, Demirbilek M et al. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium. Clin Exp Dermatol 2007; 32:675-9.
13. Roberts DT. Onychomycosis: current treatment and future challenges. Br J Dermatol 1999; 141 (Suppl. 56):1-4.
14. Jackson CJ, Barton RC, Kelly SL et al. Strain identification of Trichophyton rubrum by specific amplification of subrepeat elements in the ribosomal DNA nontranscribed spacer. J Clin Microbiol 2000; 38:4527-34.
15. Evans EG. The rationale for combination therapy. Br J Dermatol 2001; 145 (Suppl. 60):9-13.
16. Hancock RE, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother 1999; 43:1317-23.
17. Malina A, Shai Y. Conjugation of fatty acids with different lengths modulates the antibacterial and antifungal activity of a cationic biologically inactive peptide. Biochem J 2005; 390:695-702.
18. Makovitzki A, Avrahami D, Shai Y. Ultrashort antibacterial and antifungal lipopeptides. Proc Natl Acad Sci USA 2006; 103:15997-6002.
19. Makovitzki A, Shai Y. pH-dependent antifungal lipopeptides and their plausible mode of action. Biochemistry 2005; 44:9775-84.
20. Barchiesi F, Giacometti A, Cirioni O et al. In vitro activity of the synthetic lipopeptide PAL-Lys-Lys-NH(2) alone and in combination with antifungal agents against clinical isolates of Cryptococcus neoformans. Peptides 2007; 28:1509-13.
21. Kamysz W, Silvestri C, Cirioni O et al. In vitro activities of the lipopeptides palmitoyl (Pal)-Lys-Lys-NH(2) and Pal-Lys-Lys alone and in combination with antimicrobial agents against multiresistant gram-positive cocci. Antimicrob Agents Chemother 2007; 51:354-8.
22. Kamysz W, Kochańska B, Kȩdzia A. Stathering SV2 and its analogue. Synthesis and evaluation of antimicrobial activity. Pol J Chem 2002; 76:801-6.
23. National Committee for Clinical Laboratory Standards. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard. NCCLS document M38-P. Wayne, PA, U.S.A.: National Committee for Clinical Laboratory Standards, 1998.
24. Arikan S, Lozano-Chiu M, Paetznick V et al. In vitro synergy of aspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother 2002; 46:245-7.
25. Gupta AK, Kohli Y. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity. Br J Dermatol 2003; 149:296-305.
26. Jessup CJ, Warner J, Isham N et al. Antifungal susceptibility testing of dermatophytes: establishing a medium for inducing conidial growth and evaluation of susceptibility of clinical isolates. J Clin Microbiol 2000; 38:341-4.
27. Johnson MD, MacDougall C, Ostrosky-Zeichner L et al. Combination antifungal therapy. Antimicrob Agents Chemother 2004; 48:693-715.
28. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52:1.
29. Denning DW, Hanson LH, Perlman AM et al. In vitro susceptibility and synergy studies of Aspergillus species to conventional and new agents. Diagn Microbiol Infect Dis 1992; 15:21-34.
30. Hughes CE, Harris C, Moody JA et al. In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp. Antimicrob Agents Chemother 1984; 25:560-2.
31. Nguyen MH, Najvar LK, Yu CY et al. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother 1997; 41:1120-3.
32. Avrahami D, Shai Y. A new group of antifungal and antibacterial lipopeptides derived from non-membrane active peptides conjugated to palmitic acid. J Biol Chem 2004; 279:12277-85.
33. Makovitzki A, Baram J, Shai Y. Antimicrobial lipopolypeptides composed of palmitoyl Di-and tricationic peptides: in vitro and in vivo activities, self-assembly to nanostructures, and a plausible mode of action. Biochemistry 2008; 47:10630-6.